Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;18(6):39.
doi: 10.1007/s11912-016-0519-8.

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Aharon Ronson  1 , Ariella Tvito  1 , Jacob M Rowe  2   3
Affiliations
Review

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Aharon Ronson et al. Curr Oncol Rep. 2016 Jun.

Abstract

Patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have a dismal prognosis with less than 10 % of patients surviving 5 years. Most such patients cannot be rescued with currently available therapies, whatever the initial treatment they receive. Therefore, there is an urgent need for novel treatment options. Fortunately, over the past several years, an improved understanding of the biology of the disease has allowed the identification of rational molecular targets for therapeutic endeavors and the emergence of novel therapies has sparked great interest. This review will discuss the current treatment landscape for adult patients with relapsed and/or refractory ALL.

Keywords: Acute lymphoblastic leukemia; Blinatumomab; Chimeric antigen receptor-T; Relapsed/refractory.

PubMed Disclaimer

References

    1. Int J Nanomedicine. 2013;8:3479-88 - PubMed
    1. Lancet Oncol. 2012 Apr;13(4):403-11 - PubMed
    1. Cancer Res. 1993 Jul 15;53(14):3336-42 - PubMed
    1. Br J Haematol. 2014 May;165(4):504-9 - PubMed
    1. J Clin Oncol. 2003 Mar 15;21(6):1167-73 - PubMed

MeSH terms

Substances

LinkOut - more resources